Viatris Other Non-Current Liabilities 2010-2024 | VTRS
Viatris other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Viatris other non-current liabilities for the quarter ending December 31, 2024 were $1.939B, a 27.84% increase year-over-year.
- Viatris other non-current liabilities for 2024 were $1.939B, a 27.84% increase from 2023.
- Viatris other non-current liabilities for 2023 were $1.517B, a 13.64% decline from 2022.
- Viatris other non-current liabilities for 2022 were $1.757B, a 9.16% decline from 2021.
| Viatris Annual Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2024 | $1,939 |
| 2023 | $1,517 |
| 2022 | $1,757 |
| 2021 | $1,934 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $1,097 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $1,366 |
| 2014 | $0 |
| 2013 | $0 |
| 2012 | $0 |
| 2011 | $0 |
| 2010 | $0 |
| 2009 | $0 |
| Viatris Quarterly Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2024-12-31 | $1,939 |
| 2024-09-30 | |
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | $1,517 |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | $1,757 |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | $1,934 |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | $1,097 |
| 2018-09-30 | |
| 2018-06-30 | |
| 2018-03-31 | |
| 2017-12-31 | |
| 2017-09-30 | $1,413 |
| 2017-06-30 | |
| 2017-03-31 | |
| 2016-12-31 | |
| 2016-09-30 | |
| 2016-06-30 | $1,275 |
| 2016-03-31 | |
| 2015-12-31 | $1,366 |
| 2015-09-30 | |
| 2015-06-30 | |
| 2015-03-31 | |
| 2014-12-31 | |
| 2014-09-30 | |
| 2014-06-30 | |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | $401 |
| 2012-06-30 | $393 |
| 2012-03-31 | $384 |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| 2011-03-31 | |
| 2010-12-31 | |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | |
| 2009-12-31 | |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.516B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $143.728B | 26.96 |
| Elevance Health (ELV) | United States | $94.145B | 12.15 |
| CVS Health (CVS) | United States | $81.986B | 10.19 |
| Cencora (COR) | United States | $53.983B | 18.77 |
| Natera (NTRA) | United States | $21.477B | 0.00 |
| DiDi Global (DIDIY) | China | $21.462B | 32.57 |
| BioMerieux (BMXMF) | France | $15.263B | 0.00 |
| Solventum (SOLV) | United States | $12.941B | 13.70 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.036B | 0.00 |
| Revvity (RVTY) | United States | $11.610B | 19.98 |
| Doximity (DOCS) | United States | $11.396B | 59.26 |
| ICON (ICLR) | Ireland | $11.324B | 10.53 |
| CochLear (CHEOY) | Australia | $11.195B | 0.00 |
| Medpace Holdings (MEDP) | United States | $9.017B | 23.95 |
| Avantor (AVTR) | United States | $8.859B | 12.87 |
| HealthEquity (HQY) | United States | $8.361B | 41.13 |
| Sonic Healthcare (SKHHY) | Australia | $8.215B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.027B | 13.77 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| Bausch + Lomb (BLCO) | Canada | $4.202B | 24.77 |
| BrightSpring Health Services (BTSG) | United States | $3.894B | 36.05 |
| Sotera Health (SHC) | United States | $3.832B | 21.77 |
| Surgery Partners (SGRY) | United States | $2.982B | 38.77 |
| Alignment Healthcare (ALHC) | United States | $2.952B | 0.00 |
| Concentras Parent (CON) | United States | $2.771B | 16.01 |
| Organon (OGN) | United States | $2.264B | 2.41 |
| Ardent Health Partners (ARDT) | United States | $2.121B | 9.04 |
| Premier (PINC) | United States | $2.101B | 14.38 |
| Progyny (PGNY) | United States | $1.886B | 41.51 |
| PACS (PACS) | United States | $1.698B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.683B | 64.83 |
| GoodRx Holdings (GDRX) | United States | $1.669B | 31.07 |
| Teladoc Health (TDOC) | United States | $1.289B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.234B | 9.39 |
| Agilon Health (AGL) | United States | $1.229B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.000B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| CareDx (CDNA) | United States | $0.911B | 14.23 |
| AMN Healthcare Services Inc (AMN) | United States | $0.866B | 8.11 |
| Embecta (EMBC) | United States | $0.725B | 4.89 |
| QDM (QDMI) | Hong Kong, SAR China | $0.690B | 0.00 |
| Nutex Health (NUTX) | United States | $0.689B | 13.50 |
| Enhabit (EHAB) | United States | $0.530B | 43.58 |
| InnovAge Holding (INNV) | United States | $0.513B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.513B | 13.59 |
| Sonida Senior Living (SNDA) | United States | $0.512B | 0.00 |
| LifeMD (LFMD) | United States | $0.389B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.363B | 0.00 |
| SBC Medicals (SBC) | United States | $0.359B | 0.00 |
| Beauty Health (SKIN) | United States | $0.220B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.202B | 0.00 |
| Oncology Institute (TOI) | United States | $0.193B | 0.00 |
| DocGo (DCGO) | United States | $0.147B | 24.08 |
| Sera Prognostics (SERA) | United States | $0.087B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.087B | 0.00 |
| KindlyMD (KDLY) | United States | $0.082B | 0.00 |
| OncoCyte (OCX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.076B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.054B | 0.00 |
| Biodesix (BDSX) | United States | $0.053B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.031B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| ModivCare (MODV) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.011B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |